Telitacicept Receives Two NMPA Approvals in China, Including First-Ever for Sjögren's Disease
Summary
Vor Biopharma announced that its collaborator RemeGen received two NMPA approvals in China for telitacicept: one for Sjögren's disease (the first-ever global approval for this indication) and another for IgA nephropathy. These approvals validate the drug's potential and support Vor Bio's global development efforts.
Key Events
-
NMPA Approval for Sjögren's Disease
Telitacicept received approval from China's NMPA for Sjögren's disease (SjD), marking the first-ever regulatory approval for this indication globally and the first approved therapy for SjD in China.
-
NMPA Conditional Approval for IgA Nephropathy
Telitacicept also received conditional approval from China's NMPA for IgA nephropathy (IgAN), becoming the first and only approved BAFF/APRIL-targeting therapy for this condition.
-
Validation for Global Development
These approvals in China, based on positive Phase 3 data, significantly validate telitacicept's mechanism of action and clinical efficacy, supporting Vor Biopharma's ongoing global Phase 3 trials for Sjögren's disease and generalized myasthenia gravis.
-
Fifth Indication for Telitacicept
Sjögren's disease marks the fifth indication approval for telitacicept in China, further demonstrating its broad potential across autoimmune diseases.
Analysis
These NMPA approvals in China for telitacicept, particularly the first-ever regulatory approval for Sjögren's disease globally, provide significant validation for Vor Biopharma's lead asset. While RemeGen holds commercial rights in China, these milestones de-risk telitacicept and strengthen the clinical evidence supporting Vor Bio's ongoing global Phase 3 trials for Sjögren's disease and generalized myasthenia gravis. This positive news is crucial for a clinical-stage biotech company that recently reported substantial losses and raised capital to extend its runway.
At the time of this filing, VOR was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $720.1M. The 52-week trading range was $3.63 to $65.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.